

BAXDELA - (EQ 450MG BASE ; Tablet)

Generic Name	DELAFLOXACIN MEGLUMINE	Innovator	Melinta
Dosage	EQ 450MG BASE ; Tablet	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	BAXDELA is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

BAXDELA - (EQ 300MG BASE/VIAL ; Powder)

Generic Name	DELAFLOXACIN MEGLUMINE	Innovator	Melinta
Dosage	EQ 300MG BASE/VIAL ; Powder	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	BAXDELA is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.